Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

arrow_back

Babbler permet aux journalistes et communicants de collaborer plus simplement.

En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !

Leurs espaces presse sont sur Babbler :

Vous êtes à 1 clic de l'inscription !

Précédent

Content de vous revoir !

Communiqué de presse

Immune Anti-Inhibitor Market - Global Industry, Analysis and Forecast till 2026
timer minutes de lecture minute de lecture

Copier le lien
Immune system of haemophilia patients' produces antibodies called as inhibitors, which acts against the administered therapy.
<p>Immune anti-inhibitor</p>

Cliquez sur l'image pour obtenir le format original

Immune anti-inhibitor

Researchers are working on analyzing the risks associated with use of replacement factors, as in which replacement factors are more prone to facilitate development of antibodies. For instance, World Federation of Haemophilia (WFH) announced results from study published in journal ‘Blood’ in 2014, which demonstrated higher incidence of inhibitor development after treatment with Kogenate FS/Bayer/Helixate NexGen replacement factor. The World Federation of Haemophilia has requested the U.S. Food & Drug Administration and the European Medicine Agency (EMA) to examine the data. Such studies are expected to reduce the instances of haemophilia with antibodies. Furthermore, therapies such as Immune Tolerance Induction (ITI) which involve continuous treatment with replacement factors till they are no longer considered as foreign bodies by inhibitors are expected to restrain the growth of the market.

Key players operating in global immune anti-inhibitor market include Shire Plc, Baxter International, Inc, F. Hoffmann La Roche Ltd., Novo Nordisk A/S, and CSL Behring.

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/1519

For instance, Roche is working on monoclonal antibodies for treatment of haemophilia with inhibitors. In June 2017, Roche’s emicizumab (Hemlibra) showed positive results in Phase III studies in haemophilia A with inhibitors. The U.S. Food & Drug Administration (FDA) approved Emicizumab (Hemlibra) once – weekly subcutaneous therapy for haemophilia A with inhibitors in September 2017. Emicizumab is a monoclonal antibody designed to facilitate blood clotting process by combining factors IXa and X. Moreover, the Center for Disease Control and Prevention (CDC) is examining the etiology of the haemophilia with inhibitors, which could help in development of novel therapies to boost growth of the immune anti-inhibitor market.

Pipeline for haemophilia with inhibitors is also promising as few of the manufacturers are working on novel therapies for the condition. One such organization Catalyst Biosciences has a Factor VIIa marzeptacog alfa (activated) in the clinical trials for haemophilia A or B with inhibitors. Moreover, Bioverativ Inc., a Sanofi S. A.'s subsidiary has FVIIIa mimetic bispecific antibody under studies for haemophilia A with inhibitors. Multiple products are pipeline which are expected to receive approval over the forecast period, this in turn is projected to boost growth of the immune anti-inhibitor market over the forecast period.

Request for complete TOC of this report @ https://www.coherentmarketinsights.com/ongoing-insight/toc/1519

Immune system of haemophilia patients’ produces antibodies called as inhibitors, which acts against the administered therapy. Haemophilia patients are administered either plasma-derived or recombinant replacement blood factor concentrates as medication therapy, which help in blood clotting. However, the inhibitors falsely target replacement factor concentrates as a foreign substance. These antibodies are developed after the patient has been administered with blood factor FVIII concentrate. Inhibitors act after 10 to 20 days of first exposure to factor replacement therapy. Most of these inhibitors remain in the blood for short time and disappear without treatment. However, more persistent inhibitors is a serious adverse event with respect to treatment of Haemophilia A. Commercially available anti-inhibitor coagulant complex includes FEIBA and FEIBA VH Immuno.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, 

#3200 

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

  • Fitness
  • Health & Medicine
  • Medicine
  • Science & Technology

Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici

  • Fitness
  • Health & Medicine
  • Medicine